Two new oral disease modifying therapies in relapsing remitting multiple sclerosis

被引：0
作者：
Lebrun, C. [1 ]
de Seze, J. [2 ]
机构：
[1] Hop Louis Pasteur, Serv Neurol, F-06002 Nice 1, France
[2] Hop Hautepierre, Serv Neurol, F-67000 Strasbourg, France
来源：
REVUE NEUROLOGIQUE | 2014年 / 170卷 / 12期
关键词：
PLACEBO-CONTROLLED PHASE-3; DOUBLE-BLIND; TERIFLUNOMIDE; TRIAL; BG-12;
D O I：
10.1016/j.neurol.2014.11.002
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：721 / 722
页数：2
相关论文
共 50 条
  • [41] Oral Disease-Modifying Treatments for Relapsing Multiple Sclerosis: A Likelihood to Achieve No Evidence of Disease Activity or Harm Analysis
    Papadopoulos, Dimitrios
    Mitsikostas, Dimos-Dimitrios D.
    CNS DRUGS, 2018, 32 (11) : 1069 - 1078
  • [42] Effect of disease-modifying therapies on brain volume in relapsing-remitting multiple sclerosis: Results of a five-year brain MRI study
    Khan, Omar
    Bao, Fen
    Shah, Megha
    Caon, Christina
    Tselis, Alexandros
    Bailey, Ronald
    Silverman, Bruce
    Zak, Imad
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2012, 312 (1-2) : 7 - 12
  • [43] Impact of disease-modifying therapies on MRI outcomes in patients with relapsing-remitting multiple sclerosis: A systematic review and network meta-analysis
    Bose, Debdipta
    Ravi, Renju
    Maurya, Miteshkumar
    Pushparajan, Libby
    Konwar, Mahanjit
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2022, 61
  • [44] Cost-utility of First-line Disease-modifying Treatments for Relapsing Remitting Multiple Sclerosis
    Soini, Erkki
    Joutseno, Jaana
    Sumelahti, Marja-Liisa
    CLINICAL THERAPEUTICS, 2017, 39 (03) : 537 - +
  • [45] Current management of relapsing-remitting multiple sclerosis
    Sedal, L.
    Wilson, I. B.
    McDonald, E. A.
    INTERNAL MEDICINE JOURNAL, 2014, 44 (10) : 950 - 957
  • [46] Teriflunomide for the treatment of relapsing-remitting multiple sclerosis
    Miller, Aaron E.
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2015, 11 (02) : 181 - 194
  • [47] Update on disease-modifying therapies for multiple sclerosis
    Vargas, Diana L.
    Tyor, William R.
    JOURNAL OF INVESTIGATIVE MEDICINE, 2017, 65 (05) : 883 - 891
  • [48] Safety of Newer Disease Modifying Therapies in Multiple Sclerosis
    Jalkh, Georges
    Abi Nahed, Rachelle
    Macaron, Gabrielle
    Rensel, Mary
    VACCINES, 2021, 9 (01) : 1 - 30
  • [49] Comparative safety of high-efficacy disease-modifying therapies in relapsing-remitting multiple sclerosis: a systematic review and network meta-analysis
    Sladowska, Katarzyna
    Kawalec, Pawel
    Holko, Przemyslaw
    Osiecka, Oktawia
    NEUROLOGICAL SCIENCES, 2022, 43 (09) : 5479 - 5500
  • [50] Efficacy and safety of BG-12 (dimethyl fumarate) and other disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis: a systematic review and mixed treatment comparison
    Hutchinson, Michael
    Fox, Robert J.
    Havrdova, Eva
    Kurukulasuriya, Nuwan C.
    Sarda, Sujata P.
    Agarwal, Sonalee
    Siddiqui, Mohd Kashif
    Taneja, Ankush
    Deniz, Baris
    CURRENT MEDICAL RESEARCH AND OPINION, 2014, 30 (04) : 613 - 627
12345